The following organizations and research projects received grant funding awards:

**Florida Atlantic University, $199,280**
- Development of a diagnostic for rapid detection of Zika - $199,280

**Florida International University, $2,183,004**
- Development of nanoscale approaches for Zika virus and therapeutics - $1,984,536
- Identifying molecular targets for spatial mosquito repellent design - $198,468

**Florida State University, $2,169,675**
- Human pharmacokinetics of niclosamide - $1,113,645
- Mechanism of centrosome activation by Zika and the evaluation of targeted pharmacological interventions - $856,750
- Fetal brain exosomes in the maternal circulation for the detection of Zika virus infected fetuses - $199,280

**Moffitt Cancer Center, $199,280**
- Cellular targets of Zika-encoded proteins and microcephaly - $199,280

**Nova Southeastern University, $198,886**
- Comparative analysis of Zika induced antiviral response mechanisms in understudied cell populations - $198,886

**The Scripps Research Institute, $199,280**
- Development of screening tools to search for compounds inhibiting the essential Zika virus NS3 protease - $199,280

**University of Central Florida, $1,297,817**
- Point of care assay development for diagnosis of Zika viremia - $199,280
- Universal nucleic acid recognition platform for detection of Zika - $198,875
- Zika virus activation and inhibition of human complement immunity - $500,408
- Utilization of in utero diffusion tensor magnetic resonance imaging to evaluate neurological disorders caused by Zika virus - $199,254
- Point of care diagnostic platform based on visual split deoxyribozyme sensors - $200,000

**University of Florida, $2,922,999**
- Identification of potent neutralizing Zika virus antibodies using single-cell analysis technology - $868,744
- Rapid detection of Zika and other mosquito borne pathogens - $199,144
- Rapid diagnostic test for Zika virus in dried blood - $198,812
- Multiplexed detection platform for point-of-service testing of Zika - $515,377
- Identification of antiviral therapies for the treatment of Zika using existing drugs - $1,140,922

**University of Miami, $13,170,784**
- Development of antibody-based Zika diagnostics - $1,141,585
- Development and testing of novel secreted GP96-Ig Zika virus vaccine - $981,901
- Prospective longitudinal assessment of infants of mothers with Zika infection in pregnancy - $1,989,654
- Rapid RNA test for Zika - $199,280
- Longitudinal brain MRI characterization of Zika-positive and exposed children - $1,141,457
- Early diagnosis and rehabilitation for craniofacial disorders in congenital Zika - $1,140,125
- Evaluation of novel Zika vaccines - $1,141,582
- Investigation into cardiovascular complications related to Zika infections - $963,109
- Evaluation of infants for Zika-related organ damage - $1,989,654
- Identification of the duration of Zika persistence to guide reproductive health decisions - $1,141,582
- Development of nano-formulations of anti-heminthic drugs for Zika therapy and prevention - $1,141,582
- Development of rapid diagnostic assay for Zika virus infection - $199,273

**University of South Florida, $2,458,995**
- USF Integrated Clinical Trial Network structuring and enhancement of for execution of Zika virus vaccine and diagnostic clinical trials - $1,117,413
- Cellular and molecular mediators of Zika virus replication and mechanisms of transmission - $1,141,582
- Rapid identification of natural products with antiviral activity against Zika - $200,000